**Question:** The lowest recurrence rate in duodenal ulcer treatment is seen with -

A. Proton pump inhibitors (PPIs)
B. H2 receptor antagonists
C. Antacids
D. Mixed H2 receptor antagonists and antacids

**Core Concept:** In treating duodenal ulcers, the choice that results in the lowest recurrence rate is associated with the most effective inhibition of gastric acid secretion.

**Why the Correct Answer is Right:** Proton pump inhibitors (PPIs) are the most potent class of drugs for inhibiting gastric acid secretion, leading to a lower recurrence rate compared to other options.

**Why Each Wrong Option is Incorrect:**

A. H2 receptor antagonists (e.g., cimetidine, ranitidine) are less potent than PPIs in inhibiting gastric acid secretion, resulting in higher recurrence rates.
B. Antacids (e.g., calcium carbonate, magnesium hydroxide) neutralize gastric acid but do not inhibit its secretion, leading to higher recurrence rates.
C. Mixed H2 receptor antagonists and antacids (e.g., ranitidine and ranitidine-calcium carbonate combination) provide only partial inhibition of acid secretion, contributing to higher recurrence rates.

**Clinical Pearl / High-Yield Fact:** The optimal treatment for recurrent duodenal ulcers involves using PPIs, as they offer the most effective suppression of gastric acid secretion, thereby reducing the risk of ulcer recurrence.

**Correct Answer:** Proton pump inhibitors (PPIs)

**Explanation:** Proton pump inhibitors (PPIs) are the most potent anti-acid medications, inhibiting the final stage of gastric acid production - the H+/K+-ATPase enzyme in the gastric parietal cells. This results in a more profound inhibition of gastric acid secretion as compared to H2 receptor antagonists (e.g., cimetidine, ranitidine) and antacids, which only neutralize stomach acid or offer partial inhibition. Combining H2 receptor antagonists with antacids (e.g., ranitidine-calcium carbonate) does not enhance the anti-acid effect, and may even lead to gastrointestinal side effects due to calcium overload. Therefore, PPIs are the preferred choice for reducing the recurrence of duodenal ulcers, as they offer a more significant suppression of gastric acid secretion and thus lower the risk of ulcer recurrence.